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Abstract
Dynamic treatment regimens (DTRs) are sequential treatment decisions tailored by patient’s 
evolving features and intermediate outcomes at each treatment stage. Patient heterogeneity and the 
complexity and chronicity of many diseases call for learning optimal DTRs that can best tailor 
treatment according to each individual’s time-varying characteristics (eg, intermediate response 
over time). In this paper, we propose a robust and efficient approach referred to as Augmented 
Outcome-weighted Learning (AOL) to identify optimal DTRs from sequential multiple 
assignment randomized trials. We improve previously proposed outcome-weighted learning to 
allow for negative weights. Furthermore, to reduce the variability of weights for numeric stability 
and improve estimation accuracy, in AOL, we propose a robust augmentation to the weights by 
making use of predicted pseudooutcomes from regression models for Q-functions. We show that 
AOL still yields Fisher-consistent DTRs even if the regression models are misspecified and that an 
appropriate choice of the augmentation guarantees smaller stochastic errors in value function 
estimation for AOL than the previous outcome-weighted learning. Finally, we establish the 
convergence rates for AOL. The comparative advantage of AOL over existing methods is 
demonstrated through extensive simulation studies and an application to a sequential multiple 
assignment randomized trial for major depressive disorder.
Keywords
adaptive intervention; individualized treatment rule; machine learning; outcome-weighted 
learning; personalized medicine; Q-learning; SMARTs
1 | INTRODUCTION
Technology advances are revolutionizing medical research by collecting rich data from 
individual patient (eg, clinical assessments, genomic data, and electronic health records) for 
clinical researchers to meet the promise of individualized treatment and health care. The 
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availability of comprehensive data sources provides new opportunities to deeply tailor 
treatment in the presence of patient heterogeneity and the complexity and chronicity of 
many diseases. Dynamic treatment regimens (DTRs),1 also known as adaptive treatment 
strategies,1 multistage treatment strategies,2 or treatment policies,3 are a sequence of 
treatment decisions adapted to the time-varying clinical status of a patient. Moreover, DTRs 
are necessary to treat complex chronic disorders such as major depressive disorder (MDD) 
when some patients fail to achieve remission with a first-line treatment.4
Sequential multiple assignment randomized trials (SMARTs), in which randomization is 
implemented at each treatment stage, have been advocated5 to evaluate any DTR with causal 
interpretation. Using data collected from SMARTs, numerous methods have recently been 
developed to estimate optimal DTRs.6–13 See also the works of Chakraborty and Moodie14 
and Kosorok and Moodie15 for a detailed review of the current literature. Of all the methods, 
machine learning methods have received attention because of their robustness and 
computational advantages. For example, Q-learning16 was used to analyze SMART data by 
Zhao et al9 and Murphy et al.17 In this learning algorithm, the optimal treatment at each 
stage is derived from a backward induction by maximizing the so-called Q-function (“Q” 
stands for “quality of action”), which is estimated via a regression model. To avoid model 
misspecification in Q-learning, Zhao et al10 proposed outcome-weighted learning (OWL) to 
estimate the optimal treatment rules by directly optimizing the expected clinical outcome in 
a single-stage trial. They demonstrated in numerical studies that OWL outperforms Q-
learning in small sample-size settings with many tailoring variables. Later, Zhao et al18 
generalized OWL to estimating optimal DTRs in a multiple-stage trial and demonstrated the 
superior performance to existing methods. However, in the aforementioned work,18 since the 
weights at each stage of the estimation must be the optimal outcome increment in the future 
stages, only patients whose later treatments are optimal can be used for estimation. 
Consequently, a proportion of data have to be discarded from one stage to another in their 
backward learning algorithm, resulting in significant information loss and thus large 
variability of the estimated DTRs.
In this paper, we propose a hybrid approach, namely Augmented Outcome-weighted 
Learning (AOL), to integrate OWL and regression models for Q-functions for estimating the 
optimal DTRs. Similar to OWL, the proposed method relies on weighted machine learning 
algorithms in a backward induction. However, the weights used in AOL are constructed by 
augmenting optimal outcomes for all patients, including those whose later stage treatments 
are nonoptimal. The augmentation is obtained using prediction from the regression models 
for Q-functions. Thus, AOL performs augmented outcome-weighted learning using the 
regression models for Q-functions as augmentation.
There are several novel contributions in this work as compared with previous works.10,18 
First, for single-stage randomized trials, AOL generalizes OWL to allow for negative 
outcome values instead of adding an arbitrarily large constant, which may lead to numeric 
instability. Second, by using weights based on residuals after removing prognostic effects 
that are obtained from the observed outcomes, AOL reduces the variability of weights in 
OWL to achieve less variable DTR estimation. Third, AOL simultaneously takes advantage 
of the robustness of nonparametric OWL and makes use of model-based approaches to 
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utilize data from all subjects. Fourth, AOL is theoretically shown to yield the same 
asymptotic bias as OWL but smaller stochastic variability because of a better weighting 
scheme and thus guarantees efficiency gain. Moreover, AOL is proved to yield the correct 
optimal DTRs even if the regression models assumed in the augmentation are incorrect and 
thus maintains the robustness of OWL.
The rest of this paper is organized as follows. In Section 2, we review some concepts for 
DTR, Q-learning, and OWL and introduce AOL for single-stage and multiple-stage studies. 
The last part of Section 2 presents theoretical properties of AOL. In particular, we provide 
stochastic error bounds for AOL and demonstrate its smaller stochastic variability when 
compared with OWL; we further derive a fast convergence rate for AOL. Section 3 shows 
the results of extensive simulation studies to examine the performance of AOL compared 
with Q-learning and OWL. In Section 4, we present real data analysis results from the 
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial4 for MDD. Lastly, 
we conclude with a few remarks in Section 5.
2 | METHODOLOGIES
2.1 | Dynamic treatment regimes and outcome weighted learning
We start by introducing notation for a K-stage DTR. For k = 1, 2, … , K, denote Xk as the 
observed subject-specific tailoring variables collected just prior to the treatment assignment 
at stage k. Denote Ak as the treatment assignment taking values in { −1, 1}, and Rk as the 
clinical outcome (also known as the “reward”) post the kth-stage treatment. Larger rewards 
may correspond to better functioning or fewer symptoms depending on the clinical setting. 
A DTR is a sequence of decision functions, 𝒟 = 𝒟1, 𝒟2, …, 𝒟K , where 𝒟K maps the 
domain of patient health history information, Hk = (X1, A1, R1, … , Ak−1, Rk−1, Xk), to the 
treatment choices in {−1, 1}. Corresponding to each 𝒟, a value function, denoted by 𝒱 𝒟 , 
is defined as the expected reward given that the treatment assignments follow regimen 𝒟.12 
Mathematically, 𝒱 𝒟 = E𝒟 ∑k = 1K Rk = ∫ ∑k = 1K RkdP𝒟, where 𝒫𝒟 is the probability 
measure generated by random variables (X1, A1, R1, … , XK,AK, RK) given that 
Ak = 𝒟k Hk  and E𝒟 is the expectation with respect to this measure. Hence, the goal of 
personalized DTRs is to find the optimal DTRs that maximize the value function.
To evaluate the value function of a DTR in a SMART, a potential outcome framework in 
causal inference literature is used. The potential outcome in our context is defined as the 
outcome of a subject had he or she followed a particular treatment regimen, possibly 
different from the observed regimen in the actual trial. Several assumptions are required to 
infer the value function of a DTR, including the standard stable unit treatment value 
assumption and the no unmeasured confounders assumption.6,19 In a SMART, the no 
unmeasured confounders assumption is automatically satisfied because of the virtue of 
sequential randomization. Furthermore, we need the following positivity assumption: let 
𝜋k(a, h) denote the treatment assignment probability, P(Ak = a|Hk = h), which is given by 
design so known to investigators in a SMART. We assume that, for k = 1, … , K and any a ∈ 
{−1, 1} and hk in the support of Hk, 𝜋k(a, hk) = P(Ak = a|Hk = hk) ∈ [c,c̃], where 0 < c ≤ c̃ < 
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1 are two constants. That is, the positivity assumption requires that each DTR has a positive 
chance of being observed.
Under these assumptions, if we let P denote the probability measure generated by (Xk,Ak, 
Rk) for k = 1, … , K, then according to the work of Qian and Murphy,12 it can be shown that 
P𝒟 is dominated by P and
𝒱 𝒟 = E









Consequently, the goal is to find the optimal treatment rule 𝒟∗ = 𝒟1
∗, …, 𝒟K
∗  that 
maximizes the above expectation. Note that 𝒟k is usually given as the sign of some decision 
function fk. Without confusion, we sometimes express the value function as 𝒱 f 1, …, f K  to 
emphasize its dependence on the decision functions.
Denote data collected from n i.i.d. subjects in a SMART at stage k as (Aik, Hik, Rik) for i = 
1, … , n, k = 1, … , K. Recently, outcome-weighted learning (Zhao et al), abbreviated as 
OWL, was proposed to estimate the optimal treatment regimes. Specifically, Zhao et al 
proposed a backward induction to implement OWL, where at stage k, they used only the 
subjects who followed the estimated optimal treatment regimens after stage k in the 
optimization algorithm. That is, the optimal rule 𝒟k Hk = sign f k Hk  solves a weighted 




n ∑i = 1
n
ϕ Aik f k Hik
∑ j = kK Ri j
πik
I Ai, k + 1 = 𝒟k + 1 Hi, k + 1 , …, AiK = 𝒟K HiK
∏ j > k πi j
+ λn
∥ f k ∥
2 ,
(2)
where Ø(x) = max(0, 1 − x) is the hinge loss πi j = π j Ai j, Hi j , 𝒟 j Hi j  is the estimated 
optimal rule at stage j from the backward learning algorithm, and ∥f∥ is some norm defined 
in a given metric space, ℋ, usually a reproducing kernel Hilbert space (RKHS), for f. 
However, as discussed before, the use of only those subjects who followed the optimal 
regimen in future stages may result in information loss, especially when K is not small. 
Furthermore, the work of Zhao et al10 suggests to subtract a constant from Rik to ensure a 
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positive weight in the optimization algorithm, where the choice of constant is arbitrary and 
can be numerically influential in the above optimization.
2.2 | AOL with K = 1 stage
We first describe the proposed method, namely AOL, under the single-stage randomized trial 
setting (K = 1). The main idea of AOL is to improve OWL by replacing R1 in (1) by some 
surrogate variable, which should give the same optimal decision rule but with less variability 
in the empirical estimation of (2).
Note that, for any integrable function s(H1) and for 𝒟 H1 = sign f k Hk , it holds that
𝒱 𝒟 = E
I A1 f H1 > 0 R1
π1 A1, H1
= E
I A1 f H1 > 0 R1 − s H1
π1 A1, H1
+ E s H1
= E
R1 − s H1
π1 A1, H1
I A1sign R1 − s H1 f H1 > 0 + E s H1 − E




where x− = −min(0, x). Therefore, maximizing V(D) is equivalent to maximizing
E
R1 − s H1
π1 A1, H1
I A1sign R1 − s H1 f H1 > 0 .
This suggests that, if we choose a surrogate variable, R1 = R1 − s H1 , to replace R1 and 
solve a similar problem to (2), where the weights are changed to Ri1 /πi1 and the class labels 
become Ai1sign Ri1 , then we expect to still obtain a consistent estimator of the optimal DTR.
Specifically, the proposed AOL for the K = 1 stage consists of the following two steps.
Step 1. Use data (Ri1,Hi1) to obtain an estimator s H1 = γ0 + γ1
TH1 by fitting a least squares 
regression or a penalized least squares regression if Hi1 is high dimensional.
Step 2. Obtain Ri1 = Ri1 − s Hi1  for each subject and fit a weighted support vector machine 
(SVM) to estimate the decision function f1, where the weights are Ri1 /πi1 and the class 





ϕ(Ai1sign(Ri1) f 1(Hi1)) + λn ∥ f 1 ∥ .
The function class for f1 is from an RKHS with either a linear kernel or a Gaussian kernel, 
which are the most popular choices in practice, although the proposed method can be 
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applied with any kernels. Computationally, this minimization can be carried out using 
quadratic programming.20 Finally, the optimal DTR, 𝒟1
∗, is estimated as 
𝒟1 H1 = sign f 1 H1 .
Remark 1. A heuristic interpretation of AOL is the following: first, learning DTR is essential 
to learn the qualitative interaction between A1 and H1, so the removal of any main effects 
s(H1) from R1 has no influence; second, for a subject with large observed value of |R1 − 
s(H1)|, the above maximization implies that the optimal treatment assignment should be 
likely to remain the same as the actual treatment he/she is observed to receive in a trial if R1 
− s(H1) is positive but should be the opposite if negative. Furthermore, there are intuitive 
advantages to use R1 to replace R1 and use R1 /π1 A1, H1  as the new weight. When s(H1) is 
chosen appropriately, the resulting R1 is less variable, so we expect that it may lead to a less 
variable DTR estimator using empirical observations. Moreover, since the proposed new 
weights are nonnegative, this guarantees a convex optimization problem when solving (2). In 
contrast, in the original OWL, when the weights in (2) are negative, they suggested 
subtracting an arbitrarily small constant from the weights to make it positive. This shifting of 
negative weights has been demonstrated to be unstable in numerical studies.
2.3 | AOL with K = 2 stages
Next, we consider K = 2. Because DTRs aim to maximize the expected cumulative rewards 
across all stages, the optimal treatment decision rule at the current stage must depend on 
subsequent decision rules and future clinical outcomes or rewards under those rules. This 
observation motivates us to use a backward procedure similar to the backward induction in 
Q-learning and OWL in the work of Zhao et al.18 To estimate the optimal treatment rule at 
stage 2, AOL has the same two steps as in Section 2.2.
Step 2–1. Use data (Ri2, Hi2) to obtain an estimator s2 H2 = γ0 + γ1
TH2 by fitting a least 
squares regression or a penalized least squares regression if Hi2 is high dimensional.
Step 2–2. Obtain Ri2 = Ri2 − s2 Hi2  for each subject and fit a weighted SVM to estimate the 
decision function f2, where the weights are Ri2 /πi2, and the class labels are Ai2sign Ri2 . That 





ϕ(Ai2sign(Ri2) f (Hi2)) + λn ∥ f ∥ .
Thus, the estimated optimal DTR at stage 2 is given by 𝒟2 H2 = sign f 2 H2 .
Now, we consider the estimation of the optimal stage 1 treatment rule. For this purpose, a 
key outcome variable is the so-called Q-function, denoted by Q2, which is the future reward 
increment at future stages if a subject is assigned to the optimal treatment in those stages. If 
Q2 were observed for each subject, then the optimal treatment rule at stage 1 would be 
Liu et al. Page 6













estimated using OWL with R1 + Q2 as the outcome part of the weight. For the subjects 
whose treatment assignments at stage 2 are the same as the optimal treatment rule 𝒟2
∗, it is 
clear that Q2 = R2, and thus, their weights are observed; however, for subjects whose 
treatment assignments at stage 2 are not optimal (ie, not the same as 𝒟2
∗), Q2 is not observed. 
Moreover, OWL uses only those subjects whose Q2’s are observed and multiplies by the 
inverse probability of treatment assignment.
However, if we treat missing Q2 as a missing data problem, it is well known that the use of 
only complete data for estimation may not be the most efficient method; instead, one can use 
auxiliary information prior to stage 2, namely H2, to predict Q2 through augmentation for 
those subjects with missing Q2 (ie, for those subjects whose treatment assignments at stage 2 
are not the same as the optimal treatment rule 𝒟2
∗). Define m22(H2) as an approximation to 
the optimal reward increment for subjects who receive nonoptimal treatment at stage 2. 
Following the missing data literature,21 such an augmented Q2 can be defined as




I A2 = 𝒟2
∗ H2
π2 A2, H2
− 1 m22 H2 .
Ideally, we want to choose m22(H2) as close as possible to E[Q2|H2]; however, in practice, 
because the latter is unknown, and H2 can be high dimensional, we will estimate m22(H2) as 
a linear function of H2 using a weighed least squares regression for subjects who are treated 
optimally in stage 2 as described below. To estimate the optimal stage 1 treatment rule, AOL 
has the following steps.
Step 1–1. Recall 𝒟2 H2 = sign f 2 H2 . Estimate m22(H2) = β0 + β








Ri2 − m22 Hi2
2,
and denote the resulting estimator as m22.
Step 1–2. For subject i, compute
Qi2 =
I Ai2 = D2 Hi2
πi2
Ri2 −
I Ai2 = D2 Hi2
πi2
− 1 m22 Hi2 .
Step 1–3. Obtain an estimator s1 H1  for s1(H1) = α0+α
TH1 using a least squares regression 
that minimizes
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Ri1 + Qi2 − s1 Hi1
2
and denote Ri1 = Ri1 + Qi2 − s1 Hi1 .
Step 1–4. Finally, obtain f 1 by fitting a weighted SVM with weights Ri1 /πi1 and class labels 
Ai1sign Ri1 . The optimal DTR at stage 1 is then 𝒟1 H1 = sign f 1 H1 .
Note that the last two steps (Steps 1–3 and 1–4) essentially repeat the same procedure as in 
the K = 1 stage except that the outcome is the augmented outcome variable Ri1 + Qi2 As a 
remark, when Hi2 or Hi1 is of high dimension, we recommend that a penalized least squares 
regression such as Lasso be used in Step 1–1 or Step 1–3 in practice.
Remark 2. The key idea of our proposed approach for two-stage problem is to use prediction 
models for the Q-function at stage 2 to “impute” the future reward increments for the 
subjects whose actual treatments received in the second stage are not the optimal because 
their the observed outcomes cannot be used to estimate the optimal future reward 
increments. The missingness mechanism is due to the randomization of the treatments in 
stage 2; thus, it is completely known. The proposed augmented weights in stage 1 are 
guaranteed to yield the correct optimal treatment rules. Furthermore, if the “imputation” is 
sufficiently close to the underlying true model, we expect to obtain better accuracy in 
finding the optimal rule because of using more observations.
2.4 | Generalization to more than 2 stages
When there are more than two stages, the same backward learning as in K = 2 can be 
applied, but the augmentation for those subjects with missing future optimal reward 
increments becomes more complex. First, to estimate the optimal treatment rule at stage K, 
we perform the same stage 2 steps as AOL with K = 2 (ie, Steps 2–1 and 2–2 in Section 2.3) 
but with (R2, A2, H2) replaced by (RK, AK, HK). Denote the resulting estimated decision 
function at this stage as f K HK  and denote the corresponding treatment rule as 
𝒟K HK = sign f K HK .
We then continue to estimate the optimal treatment rules at stage K − 1, K − 2, … in turn. 
Specifically, to estimate the optimal (k − 1)th-stage treatment rule, we let Mi, k
k − 1 = 1, and 
for j ≥ k, let Mik
j = I Aik = 𝒟k* Hik , …, Ai j = 𝒟 j* Hi j  denote whether subject i follows the 
optimal treatment regimens from stage k to j. From the theory of Robins8, also seen in 
Tsiatis21 and Zhang et al22, Qik, the optimal reward increment for patient i if she/he follows 
the estimated optimal rule from stage k to K, has the following expression:
Qik =
Mik
K Rik + … + RiK





∏l = kj − 1πil
I Ai j = 𝒟 j
∗ Hi j
πi j
− 1 mk j Hi j ,
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where mkj(Hij) is the optimal reward increment for subjects who receive optimal treatments 
up to stage (j − 1), ie, E Qik Hi j,Mik
j − 1 = 1 .
To implement AOL, at stage k − 1, assume that we have already obtained the estimated 
optimal rules after this stage, denoted by 𝒟k, …𝒟K. Define
Mik
j = I Aik = 𝒟k Hik , …, Ai j = 𝒟 j Hi j .
Then, the augmentation term for Qik is estimated by
Mik
K Rik + … + RiK





∏l = kj − 1πil
I Ai j = 𝒟 j Hi j
πi j
− 1 mk j Hi j , (3)





∏l = kK πik
1 − πi j




Ril −mk j Hi j
2
.
We define Ri, k − 1 = Ri, k − 1 + Qi, k − sk − 1 Hk − 1 , where sk − 1 Hk − 1  is estimated via a 
least squares regression that minimizes ∑i = 1n Ri, k − 1 + Qik − sk − 1 Hi, k − 1
2
 for 
sk − 1 Hk − 1 = α0 + α
THk − 1. Then, we will estimate f k − 1. by fitng a weighted SVM with 
weights Ri, k − 1 /πi, k − 1 and class labels Ai, k − 1sign Ri, k − 1 , ie, f k − 1 minimizes
n−1 ∑
i = 1
n Ri, k − 1
πi, k − 1
ϕ(Ai, k − 1sign(Ri, k − 1) f k − 1(Hi, k − 1)) + λn ∥ f k − 1 ∥ .
One important fact for AOL is that the estimated treatment rules are invariant even if we 
shift Rk by any constant ck for k = 1, … , K. This is because under constant translation, mkj 
will be shifted by ∑l = kK cl so Qik becomes Qik + ∑l = kK cl. Therefore, Ri, k − 1 which is the 
residual after regressing Ri, k − 1 + ck − 1 + Qik on 1 and Hi,k−1, remains unchanged, so the 
estimated treatment rule is the same as before. Finally, when Hj’s dimension is large, a 
penalized least square regression such as Lasso is recommended in the above procedure to 
obtain mk j H j .
2.5 | Software
We provide an R-package “DTRlearn” https://cran.r-project.org/web/packages/DTRlearn/
index.html on CRAN for the single- and multiple-stage implementation of our proposed 
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method (AOL) and Q-learning and O-learning as compared in the following simulation 
results and real data implementation.
2.6 | Summary of theoretical results
In the supplementary material, we provide theoretical justification for the proposed methods. 
Theorem A.1 provides an error bound for single stage AOL. We formally prove that using 
this new surrogate weight on the basis of the residuals of R1, the value loss due to using the 
estimated treatment rule f 1 has the same deterministic error bound as using the original R1; 
however, the error bound due to data randomness is smaller. In this sense, the value function 
for AOL has the same approximation bias as OWL but a smaller stochastic error 
asymptotically. Thus, AOL requires fewer observations than OWL to achieve a similar 
performance.
Theorem A.2 in the supplementary material provides the improved risk bound for multiple 
stage AOL. We formally show that the above data augmentation method using a surrogate 
function m22(H2) for subjects with missing Q2 values will not increase the approximation 
bias of the value function estimation based on f 1; furthermore, we show that compared with 
OWL, the estimation of m22(H2) from a weighted least squares in Step 1–1 always leads to a 
smaller stochastic error bound of the value function estimation. Finally, Theorem A.3 gives a 
fast convergence rate of AOL under some regularity conditions.
The key idea behind the proofs is to decompose the value function associated with the 
estimated DTR into two parts: one is the bias due to considering the decision functions fk at 
each stage from an RKHS; the other part is the stochastic error due to both the empirical 
approximation of the value function in terms of the augmented weights in the optimization. 
The former can be characterized in terms of the richness of the Hilbert space, whereas the 
latter depends on both the complexity of the function classes in the Hilbert space and, more 
importantly, the variability of the weights used in our proposed weighted SVM methods. 
The less variable the weights are, the smaller the stochastic error is. Therefore, the proposed 
method, which relies on the augmentation, tends to bring more information to reduce the 
variability in the weights.
3 | SIMULATION STUDIES
We conducted extensive simulation studies to compare AOL with existing approaches using 
the value function (reward) of the estimated optimal treatment rules. We compared three 
methods: (i) Q-learning based on linear regression models with a Lasso penalty; (ii) OWL as 
in the works of Zhao et al10,18; (iii) AOL as described in Section 2.
3.1 | Simulation settings
We simulated single-stage, two-stage, and four-stage randomized trials. In this section, we 
present the results of four-stage settings. In the supplementary material, we provide 
additional results of the single-stage (Section B.1) and two-stage (Section B.2) settings.
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In the first four-stage scenario, we simulated a vector of baseline feature variables of 
dimension 20, X1 = (X1,1, … , X1,20), from a multivariate normal distribution, where the 
first 10 variables had a pairwise correlation of 0.2, the remaining 10 variables were 
uncorrelated among one another and were also independent of the first 10 X’s, and the 
variance for X1,j was 1 for j = 1, … , 20. The reward functions were generated as follows:
R1 = X1, 1A1 + 𝒩 0, 1 ; R2 = R1 + X1, 2
2 + X1, 3
2 − 0.8 A2 + 𝒩 0, 1 ;
R3 = 2 R2 + X1, 4 A3 + X1, 5
2 + X1, 6 + 𝒩 0, 1 ; R4 = R3 − 0.5 A4 + 𝒩 0, 1 .
The randomization probabilities of treatment assignment at each stage were allowed to 
depend on the feature variables through
P A1 = 1 H1 =
1
1 + exp −0.5X1, 1
;P A2 = 1 H2 =
1
1 + exp 0.1R1
;P A3 = 1 H3 =
1
1 + exp 0.2X1, 3
;
P A4 = 1 H4 =
1
1 + exp 0.2X1, 4
.
Patient’s health history information matrix at stage k, Hk, was defined recursively by (Hk−1, 
Ak−1, Ak−1Hk−1, Rk−1), and at the first stage, it only contains the baseline feature variables, 
ie, H1 = X1. Therefore, there were p = 20 features for OWL and AOL in the first stage, 2p 
+ 2 for the second stage, and 8p + 14 variables for the fourth stage. To handle high 
dimensionality of the feature space, especially when k increases, weighted least squares with 
a Lasso penalty was used to estimate mk j, and ordinary least squares with Lasso penalty was 
used to estimate ŝk. When estimating conditional expectations in Q-learning, (Hk, Ak) was 
included in the linear regression models (the number of predictors approximately doubles 
compared to OWL and AOL), and a Lasso penalty was imposed for better fitting.
In the second four-stage scenario, we imitated a real-world scenario of treating chronic 
mental disorders,4 where the patient population consisted of several subgroups that respond 
to DTRs differently. However, because of unknown and complex treatment mechanisms, 
instead of directly observing subgroup memberships, only group-informative feature 
variables (such as clinical symptomatology measures or neuroimaging biomarkers) were 
observed. Specifically, we created 10 subgroups of equal size and let G = 1, … , 10 denote 
group. For group G = l, the optimal DTRs across 4 stages were
A jl* = 2 l/ 2 j − 1 mod2 − 1, j = 1, 2, 3, 4.
To simulate data from a SMART, we randomly generated their treatment assignments with 
equal probabilities at each stage, and for a subject in group G = l, we generated their reward 
outcomes as R1 = R2 = R3 = 0 and R4 = ∑ j = 14 A jA jl* + N 0, 1 . Furthermore, we generated 
potentially group-informative baseline feature variables, X1 = (X1,1, … , X1,30), from a 
multivariate normal distribution with means depending on group membership: for patients in 
group G = l, the center of X1,1, … , X1,10 had a group-specific mean value μl, which was 
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generated from μl ~ N(0, 5), while the means of the remaining feature variables, X1,11, … , 
X1,30, were all zero. The first 10 features had a pairwise correlation of 0.2, and the 
remaining 20 variables were uncorrelated. Therefore, only X1,1, … , X1,10 were informative 
of the patient subgroup (and thus the optimal DTRs), and the remaining variables were 
noise. Since the group membership was not observed, the available data for our analysis 
consisted of (X1, A1, A2, A3, A4, R4). For each data set, we applied Q-learning, OWL, and 
AOL to estimate the optimal rule. For OWL, we implemented the same algorithm as in the 
work of Zhao et al,18 and the minimal value of the reward outcome was subtracted from the 
outcome to ensure the weights to be positive. In this setting, the clusters and optimal 
decision boundaries are fixed for each replication but different across replications. Thus, the 
results do not depend on the specific cluster arrangements. The decision boundaries are not 
explicitly determined by the observed predictors, but they are determined by the underlying 
latent classes, which confer information from the observed predictors.
At each stage k, Hk contained baseline feature variables X1, previous stage treatment 
assignments, and products between X1 and previous stage treatments. We varied sample 
sizes in the simulations. Cross-validation was used to choose the tuning parameter in Lasso 
regressions and was used to choose the tuning parameter of the SVM (from a grid of 2−15 to 
215). The linear kernel was used for OWL and AOL. To compare all the methods, we 
calculated the value function of the corresponding estimated optimal rule using expression 
(1) as the empirical average of a large independent test data set with a sample size of 20 000.
3.2 | Simulation results
The results from 500 replicates are presented in Figures 1 and 2 and Table 1. In both 
simulation settings and for all sample sizes, AOL shows a significant advantage over OWL 
in terms of a higher value function because of augmentation and other improvements 
highlighted in previous sections. In the first setting, we observe that Q-learning has a higher 
value function than AOL but also a higher variability with a smaller sample size (n = 50, n = 
100, and n = 200). With a large sample size (n = 400), Q-learning has an empirical standard 
deviation smaller than AOL. The value function for both Q-learning and AOL increases with 
the sample size, where the former increases at a faster rate. In this setting, the linear 
regression model is a good approximation for the Q-function since the rewards were 
generated from a linear model. Therefore, Q-learning may achieve the theoretical optimal 
value faster than AOL when n increases. Comparing with OWL, AOL achieves a much 
larger value and a smaller standard deviation for all sample sizes. In the second simulation 
setting, the optimal treatment boundaries were more complicated and highly nonlinear; 
therefore, Q-learning performed the worst among the three method at all sample sizes. For 
example, it only achieves a median value of 0.717 when n = 400 compared with the true 
optimal value of 4. For a proportion of the 500 replications, no treatment by covariate 
interaction terms were selected by Lasso regression in at least one step of Q-learning. In this 
case, the optimal treatment was selected randomly to compute the value function using the 
test data. Moreover, AOL outperforms OWL and Q-learning in all cases and achieves a 
median value of 3.211 with a sample size of 400.
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For the previous two simulation scenarios, we also implemented AOL with Gaussian kernel 
with four-fold cross validation to choose the bandwidth and compared with OWL with 
Gaussian kernel. Moreover, AOL with Gaussian kernel performed similarly with linear 
kernel for AOL in the second scenario, which achieved a median of 0.851, 1.453, 2.427, 
3.400 and for the sample size of 50, 100, 200, and 400, respectively. For the first scenario, 
AOL with Gaussian kernel has a slightly worse performance than linear kernel, with a 
median value function of 4.965, 5.496, 6.295, 6.905 for sample sizes ranging from 50 to 
400. Comparatively, OWL with Gaussian kernel has the median values of 2.529, 2.952, 
3.459, 4.288 in the first scenario and 0.804, 1.043, 1.356, 1.743 in the second scenario, so 
AOL is still superior to OWL. Since the computational burden for the Gaussian kernel is 
heavier, we conclude that using a linear kernel for AOL is sufficient in these simulation 
settings. Additional simulations of the single-stage and two-stage settings are reported in the 
supplementary material (Section B). Similar comparative performances are observed.
In summary, in simulation scenario 1, the data were generated such that a linear function is 
an adequate approximation for the true cumulative rewards. Thus, Q-learning outperformed 
OWL and AOL. In simulation scenario 2, the data were generated such that the cumulative 
rewards cannot be approximated adequately by the linear models. Thus, OWL and AOL 
outperformed the value-based learning method Q-learning. Nevertheless, in all the presented 
simulation scenarios, AOL outperformed OWL, which demonstrates that the proposed AOL 
improves OWL.
4 | REAL DATA APPLICATION
We applied the proposed method to data from the STAR*D trial,4 which was a phase-IV 
multisite, prospective, multistage, randomized clinical trial to compare various treatment 
regimes for patients with nonpsychotic MDD.4 The detail of the study design is given in the 
supplementary. The aim of STAR∗D was to find the best subsequent treatment for subjects 
who failed to achieve adequate response to an initial antidepressant treatment (citalopram). 
The primary outcome was measured by the Quick Inventory of Depressive Symptomatology 
(QIDS) score ranging from 0 to 26 in the sample. Participants with a total clinician-rated 
QIDS score under 5 were considered as having a clinically meaningful response to the 
treatment and therefore in remission. Remitted patients were not eligible for any future 
treatments and entered a follow-up phase.
Following the works of Chakraborty and Moodie14 and Pineau et al,23 we focused on a two-
stage decision-making problem by combining study levels 2 and 2A as the first stage and 
treating study level 3 as the second stage. Additionally, different drugs were combined as 
one class of drugs involving selective serotonin reuptake inhibitors (SSRI) and the other 
class of drugs without SSRI. Thus, at each stage, treatment (Ak), reward outcome (Rk), and 
feature variables (Hk) were defined as follows:
A1: 1 if SSRI drugs are used and −1 SSRI drugs are not used at level 2 and 2A (stage 
1);
A2: 1 if SSRI drugs are used and −1 SSRI drugs are not used at at level 3 (stage 2);
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R1: -QIDS score at the end of first stage if remission was achieved, −½ QIDS score at 
the end of first stage if remission was not achieved;
R2: −½ QIDS score at the end of second stage;
H1: baseline QIDS score (at the beginning of the trial), the rate of change of QIDS 
score from baseline to stage 1 randomization (level 1 to level 2), participant 
preference (taking values −1, 0, or 1), and QIDS at the beginning of stage 1 
randomization;
H2: H1, the rate of change of QIDS score during stage 1, participant preference at 
stage 2 randomization, A1, and its interactions with the previous variables.
There were 1381 participants with complete feature variables for the first stage analysis, 
among whom 516 achieved remission at the end of the first stage. Among 865 nonremitted 
participants, 364 of them had entered the second stage and have complete information on the 
feature variables and outcomes. In the analysis, the patients who had remission in stage 1 
were treated as if they would have received the optimal treatments at stage 2; thus, we only 
analyzed patients who had entered stage 2 in order to estimate the optimal rule at stage 2.
To implement AOL, we followed the steps in Section 2.3, where the first-stage 
randomization probability π1 was calculated as the frequency of SSRI and non-SSRI given 
patient preference at stage 1 and the second stage randomization probability π2 was 
computed as the similar frequency and further multiplied by the nondropout proportions to 
account for missingness in this stage. More specifically, Lasso regression was implemented 
in Step 2–1, and a weighted Lasso was used for Step 2–1. For comparison, we also 
implemented Q-learning and OWL, where Lasso was used in the regression in each stage of 
Q-learning; the same π1 and π2 were used. Both gaussian and linear kernels were 
implemented for AOL and OWL. Comparison of all the methods were based on 1000 
repetitions of two-fold cross-validation: for each cross-validation, one-half data were used 
for training, and the other half were used to compute the value functions for the estimated 
DTRs. For each replication, the testing value function was computed as the empirical 
estimation following Equation (1), which is the weighted average of the cumulative rewards 
for all patients whose observed treatments agree with the estimated optimal treatments in all 
stages.
Q-learning, OWL, and AOL were compared in Figure 3. The mean baseline clinician-rated 
QIDS score in the sample was 16.71, and the mean QIDS at the start of stage 1 
randomization was 12.37. The average testing QIDS score for the optimal DTR obtained by 
AOL with Gaussian kernel was 6.733 points (sd=4.08), which outperformed Q-learning 
(7.93, sd=2.38) and OWL with Gaussian kernel (10.85, sd=1.11). Gaussian kernel yielded 
better testing value than linear kernel for both AOL and OWL; AOL with linear kernel had 
an average testing value of 8.38 (sd=3.10), which was still better than OWL with linear 
kernel (10.85, sd=0.99). Moreover, AOL-estimated rule also outperformed the one-size-fits-
all rules (eg, all subjects receive SSRI in both stages, all subjects received SSRI in the first 
stage and non-SSRI in the second and so on).
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Furthermore, we examine the coefficients of AOL fitted by a linear kernel using the 
standardized feature variables. We present the normalized effects for the optimal DTR 
obtained by AOL in Figure 4. We normalized the effect of each tailoring variable through 
dividing by the L2 norm of all coefficients of the decision rule. The baseline variables at first 
stage with strongest effects were baseline QIDS score, rate of change of QIDS in the 
previous period, and patient preference. The strongest second-stage tailoring variables were 
intermediate outcome after stage 1 treatment, starting QIDS at stage 1, and patient 
preference for the second-stage treatment.
In conclusion, the STAR∗D example demonstrates that AOL outperforms the alternative 
methods in maximizing the clinical benefits, and it also yields some insights on combining 
tailoring variables for deep tailoring and forming new treatment rules.
5 | DISCUSSION
In this work, we propose a new machine learning method, AOL, to estimate optimal DTRs 
through robust and efficient augmentation to OWL. We theoretically prove that AOL 
guarantees efficiency improvement over OWL for both K = 1 and K > 1 stages. The 
theoretical results show that AOL has the same approximation bias but a smaller stochastic 
error. Moreover, AOL achieves efficiency gain by properly constructing surrogate outcomes 
with smaller second moments. In an earlier version of this paper (https://arxiv.org/abs/
1611.02314), we provided an additional application to a SMART of children affected by 
attention deficit and hyperactive disorder. A recent publication by Zhang and Zhang24 
considered similar augmented outcomes as weights in multiple-stage estimation but used 
genetic algorithm for estimating optimal treatments. In comparison, our proposed method 
used computationally more stable large margin loss, and we rigorously justified the 
advantage of the proposed method in terms of the risk bound for the value function.
In real-world studies, it may be difficult to identify a priori which variables may serve as 
tailoring variables for treatment response. In our simulation studies, AOL has shown to be 
superior in such settings with non-treatment-differentiating noise variables and unknown 
treatment mechanisms. In addition, using a more sophisticated prediction method (eg, 
random forest) to incorporate nonlinear interactions between health history variables Hk to 
predict sk(Hk) in the step of taking residuals may be beneficial, although theoretically, a 
linear model will guarantee improved efficiency of AOL over OWL.
Clinicians may be interested in ranking the most important variables to predict patient 
heterogeneity to treatment. Biomarkers that could signal patients’ heterogeneous responses 
to various interventions are especially useful as tailoring variables. This information can be 
used to design new intervention arms in future confirmatory trials and facilitate discovering 
new knowledge in medical research. Variable selection may help construct a less noisy rule 
and avoid over-fitting. Although AOL leads to a sparse DTR in the STAR∗D example, a 
future research topic is to investigate methods that perform automatic variable selection in 
the outcome-weighted learning framework. Additionally, our current framework can easily 
handle nonlinear decision functions by using nonlinear kernels, which may improve 
performance for high-dimensional correlated tailoring variables. It is also of interest to 
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consider other kinds of decision functions such as decision trees to construct DTRs that are 
highly interpretable.
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Simulation setting 1 with four-stage design (optimal value = 10.1). AOL, Augmented 
Outcome-weighted Learning. OWL, outcome-weighted learning [Colour figure can be 
viewed at wileyonlinelibrary.com]
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Simulation setting 2 with four-stage design (optimal value = 4.0). AOL, Augmented 
Outcome-weighted Learning; OWL, outcome-weighted learning [Colour figure can be 
viewed at wileyonlinelibrary.com]
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Mean and standard error of the value function (depression symptom score, Quick Inventory 
of Depressive Symptomatology) based on 1000 repetitions of two-fold cross validation for 
Sequenced Treatment Alternatives to Relieve Depression data (lower score desirable)
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Normalized coefficients of the stage 1 tailoring variables (left panel) and stage 2 tailoring 
variables (right panel) obtained by Augmented Outcome-weighted Learning. QIDS, Quick 
Inventory of Depressive Symptomatology
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TABLE 1
Mean and median of the empirical value function for two simulation scenarios evaluated with an independent 
test data set
n
Simulation Setting 1 (Optimal Value 10.1)
Q-learning OWL AOL
Mean (SD) Median Mean (SD) Median Mean (SD) Median
50 6.786(1.119) 6.753 2.604(1.502) 2.561 6.042(0.951) 6.078
100 7.711(1.016) 6.996 3.049(1.448) 2.957 6.436(0.859) 6.415
200 8.475(0.843) 8.874 3.593(1.461) 3.486 6.865(0.756) 6.949
400 8.934(0.398) 9.034 4.566(1.265) 4.603 7.467(0.632) 7.593
n
Simulation Setting 2 (Optimal Value 4)
Q-learning OWL AOL
Mean (SD) Median Mean (SD) Median Mean (SD) Median
50 0.042(0.182) 0.003 0.764(0.522) 0.773 1.105(0.522) 1.097
100 0.103(0.281) 0.011 0.966(0.484) 0.944 1.696(0.595) 1.698
200 0.291(0.404) 0.062 1.281(0.492) 1.284 2.519(0.518) 2.568
400 0.635(0.355) 0.717 1.638(0.446) 1.626 3.177(0.421) 3.211
Abbreviations: AOL, Augmented Outcome-weighted Learning; OWL, outcome-weighted learning.
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